Mitochondrial signalling peptide MOTS-c

MOTS-c is a small signalling molecule encoded by mitochondrial DNA. In simple terms, it helps cells “understand” how to use energy and adapt to nutrient deficiency, physical activity, and other forms of stress.

MOTS-c helps cells use the glucose circulating in the bloodstream more efficiently. It may increase cellular sensitivity to insulin, allowing glucose to enter cells more easily and be converted into energy.

Simply put, MOTS-c does not replace insulin. Instead, it may help the body respond to insulin more effectively. This may contribute to maintaining normal blood glucose levels. MOTS-c belongs to a group of mitochondrial-derived peptides whose effects are still being studied.

MOTS-c activates AMPK, the cell’s internal energy sensor. AMPK detects when a cell is running low on energy and switches it into an energy-saving and recovery mode. It helps the cell use glucose and fats more actively for energy while temporarily slowing down processes that require large amounts of energy.

MOTS-c is a short linear chain composed of 16 amino acids linked by peptide bonds.

Subcutaneous administration is the main method currently being studied in humans. Subcutaneous administration has been specified in a registered clinical study of MOTS-c involving diabetes and excess body weight.

MOTS-c is available in several forms and modified variants. They differ in their chemical composition, intended method of use, and level of scientific research. Therefore, it is important not to confuse them.

Natural MOTS-c is the original human peptide consisting of 16 amino acids. When MOTS-c is mentioned without any additional clarification, this is usually the form being referred to.

Injectable MOTS-c is a solution intended for subcutaneous administration. This method of administration is being studied in clinical research.

MOTS-c free base is the free chemical form of the peptide, meaning that it is not bound to an additional salt. It may be used in the preparation of research formulations.

MOTS-c acetate is the same MOTS-c peptide presented as an acetate salt. This form may be more convenient for manufacturing, dissolution, and storage.

However, the acetate form does not turn MOTS-c into a different peptide, nor does it automatically make it stronger or more effective.

CB4211 is a modified analogue of MOTS-c. Its structure has been altered to produce specific pharmacological properties.

CB4211 has been studied as a subcutaneous injection, but it should not be considered identical to other forms of MOTS-c or used according to the same protocols.

MP is another modified analogue of MOTS-c. It was developed to penetrate cells more easily.

Intranasal and intravenous administration of MP has primarily been investigated in animal studies.

Based on the available information, free base and acetate are chemical forms of standard MOTS-c, while CB4211 and MP are separate modified analogues. All of these variants remain the subject of scientific research and should not be considered interchangeable.

This description provides a detailed explanation of the available forms of natural MOTS-c. However, other names for MOTS-c can also be found in search results and scientific publications.

The following names and spelling variants may be used:

• MOTS-c peptide
• Mitochondrial-derived peptide MOTS-c
• Mitochondrial-encoded peptide MOTS-c
• Mitochondrial open reading frame of the 12S rRNA-c — the full scientific name of MOTS-c
• Mitochondrial ORF of the 12S rRNA type-c — an abbreviated form of the full name
• Mitochondrial signalling peptide MOTS-c — a clear descriptive name for the peptide

Before purchasing MOTS-c, it is important to review reliable information explaining what the MOTS-c peptide is, how MOTS-c is used, and why MOTS-c is being studied in relation to weight management.

Once you have reviewed the available information and determined that the properties being studied are relevant to your research goals, you may proceed with ordering MOTS-c.

The Peptorius online store offers MOTS-c for purchase in European Union countries at competitive prices.